Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. - Wikidata - awgldk - TriplyDB

Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

http://www.wikidata.org/entity/Q34173955

about

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries.Proteomic identification of plasma biomarkers in uterine leiomyoma.Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis.Redox- and expression-proteomic analysis of plasma biomarkers in bladder transitional cell carcinoma.Selective isolation and analysis of glycoprotein fractions and their glycomes from hepatocellular carcinoma sera.The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure.Identification of CTLA2A, DEFB29, WFDC15B, SERPINA1F and MUP19 as Novel Tissue-Specific Secretory Factors in Mouse.Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease.Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis.A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva.A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.Identification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancer.LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.Stable knockdown of LRG1 by RNA interference inhibits growth and promotes apoptosis of glioblastoma cells in vitro and in vivo.Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome.Plasma proteomic analysis of patients infected with H1N1 influenza virus.Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer.Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis.A multiplex platform for the identification of ovarian cancer biomarkers A highly sensitive "turn-on" fluorescent sensor for the detection of human serum proteins based on the size exclusion of the polyacrylamide gel.Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel.Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein are associated with diabetic retinopathy progression.Proteomic analysis of prognostic plasma biomarkers in peripheral arterial occlusive disease.Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction.Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter.

P2860

Q33786098-D7E1069E-B610-4E42-8725-E04C68834CC7 Q34030497-ACE15971-638D-4061-9B32-2195D890D115 Q34109488-DD8A6E78-4D66-43E4-84E5-A55DC87F1C3C Q34208244-F32DD8A9-55ED-409F-BB4B-CF3120C1FE51 Q34454754-3E3FD18D-694D-42F4-B90C-8D263404A45D Q34597839-BBA44F2C-6403-4425-9D7C-4BC757A78FE1 Q35065245-E5BFB5C6-A805-4551-A897-1394730F89E3 Q35577047-BB8A3BB4-F1EB-4273-B417-44D61D783C92 Q35793694-F9415747-18F2-4F37-84E5-63966D25CB2C Q35907425-9B3F3F06-7005-4BCC-889E-153F5BD00E3D Q35948036-46A1231D-C3E9-44BB-B096-A6C8E6DD040E Q36247995-8A9FC0B6-FA27-4467-9BD7-928FAB4D53F9 Q36436952-5C0A6C49-718C-4EB5-9B67-68D3BEFC0E54 Q36513623-F9B89A68-DCF6-409B-9A45-827AAFA4EBC2 Q36560911-BFFD743F-1FB8-4078-A16D-8F0238A60DB2 Q36561699-A2AE3289-07CF-4FA2-B5A8-7371D8266998 Q36721347-D43446D7-8F5B-43DB-95DC-FE4FFB988974 Q36820532-7E9B2607-C9EF-42C2-AF4D-94860DCFC0F2 Q37064375-78075F72-32B3-4DA1-8674-793E39951427 Q38919894-12797993-A8D8-4509-A314-FD94AEBC4284 Q41952325-02EA4930-1B3B-439F-81F3-09CD656C074F Q42215171-F1B47F84-4C24-43F6-BE58-71A1D066F069 Q42288581-ACE462A7-AED6-4683-852C-F8A54214F7AD Q42371665-A7E3FBF3-841C-44E1-B684-1B7B44AA9898 Q42374131-6B15D397-0AEA-4BB0-904A-1BF61037B2DF Q44620950-4CDBCE1D-DC9F-41F4-96D8-1B4E1B7B8228 Q47154567-A09777EA-FF8E-4F60-8802-3584F90DC59F Q47932570-DACEC08F-6C27-4F69-9882-938CB6ABF883 Q48248160-6EF3A914-B0FF-4CFA-9C34-2BCE92BE660F Q50988761-E6A57C61-2C41-40A2-B439-C7766FA0F54C Q52593439-87C0AD2C-B869-4F77-B794-F500F5EC4BB9 Q53240741-4ED0CACE-928A-4C4B-BA1D-7E968ECAF575 Q55162688-403DCA40-2DF1-4367-BE58-AC8FD44549FD

P2860

Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

http://www.wikidata.org/entity/Q34173955

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@ast

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@en

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@nl

type

label

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@ast

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@en

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@nl

prefLabel

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@ast

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@en

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@nl

P1433

Q34173955-62913C5F-37EF-4E16-9140-404C4555D417

P1476

Q34173955-8FD1BC7F-324B-4434-B599-E97FA20C6402

P2093

Q34173955-0DC12ABA-2128-4228-838D-8A98153667D2

Q34173955-1CCBA648-FA58-4A4B-8C12-A53F157A4BE6

Q34173955-333C2A52-E55A-4C11-AB4D-227FD545C940

Q34173955-551AE328-1B45-4974-B94B-EEE0AA0E530D

Q34173955-82F687B2-6084-4D12-9B9D-5AAD93652454

Q34173955-B7185531-69FB-4C4F-9938-8FAE93728243

Q34173955-BD6BCBA8-89D6-412D-BE73-85E8EF7D204B

Q34173955-C8A0F93B-0B05-4C17-AE98-3EB8F46B7D19

Q34173955-CCEDB2BA-2314-46D7-A214-F8D36761FDF4

Q34173955-E1F9BF04-1AD9-4F82-BE25-28436BC1F9F4

P2860

Q34173955-08BA9870-4F8D-45DB-BB15-701D0FDEF8EE

Q34173955-09728701-FE96-4DE8-A5DB-8BCFE89FC327

Q34173955-0A9DD0B6-3510-4EC0-9819-C51B3E2B114A

Q34173955-0CFA19FB-3AD4-4758-BB03-DE1454287C38

Q34173955-0F74E6DA-12D2-48A0-A571-1B9DE94FE82C

Q34173955-11D67AF2-3BC9-4CDA-8146-8E2C23D12AD2

Q34173955-13F26A9E-A124-4831-817C-7139B838F394

Q34173955-21EA8E13-BE5E-4FB4-8B16-54E1ACFF0298

Q34173955-230E269B-D0F5-4EB4-99D1-1695492FCF4D

Q34173955-290B2002-FC9B-42C8-989E-F55E269993A1

P2888

Q34173955-85DE85B8-0E31-407B-B413-345D0863B331

P304

Q34173955-D7EDFEC1-E582-417A-8E90-40FA93BBBF47

P31

Q34173955-444CF7DD-377D-4E40-8997-ED697FE1087C

P356

Q34173955-448EC03E-721C-46A6-9565-B6653F5C25A9

P478

Q34173955-AFF88265-6DE6-4FDE-BC3E-6CFE18914A57

P50

Q34173955-8D5BD3B2-302B-450D-92D6-4D8F20710E90

P577

Q34173955-A7F082D5-A7DC-4C05-A39C-1474DCEF18B3

P5875

Q34173955-0703492E-47CB-43C8-9CFC-17982E133EB0

P6179

Q34173955-B43E9EF7-E763-4041-A830-600C79C2A217

P698

Q34173955-20E7948E-22FC-4BC4-9FC2-46D189FD9699

P921

Q34173955-DEAE713A-83E8-474B-A1F2-5381C42E831D

P932

Q34173955-5DB395B1-203E-42B7-854C-5716D07EE348

P356

P1433

Journal of Ovarian Research

P1476

Leucine-rich alpha-2-glycoprot ...... rs of ovarian cancer patients.

@en

P2093

Amy Pn Skubitz

http://www.w3.org/2001/XMLSchema#string

Benjamin Misemer

http://www.w3.org/2001/XMLSchema#string

Bruce A Witthuhn

http://www.w3.org/2001/XMLSchema#string

John D Andersen

http://www.w3.org/2001/XMLSchema#string

Katherine M Harrington

http://www.w3.org/2001/XMLSchema#string

Kristin Lm Boylan

http://www.w3.org/2001/XMLSchema#string

Melissa A Geller

http://www.w3.org/2001/XMLSchema#string

Peter Argenta

http://www.w3.org/2001/XMLSchema#string

Ronald Jemmerson

http://www.w3.org/2001/XMLSchema#string

Starchild Weivoda

http://www.w3.org/2001/XMLSchema#string

P2860

Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum

Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation

Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis

Cancer statistics, 2008

Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search

The leucine-rich repeat as a protein recognition motif

The human plasma proteome: history, character, and diagnostic prospects

SOSUI: classification and secondary structure prediction system for membrane proteins

Serum leucine-rich alpha-2-glycoprotein-1 binds cytochrome c and inhibits antibody detection of this apoptotic marker in enzyme-linked immunosorbent assay.

Influence of clotting time on the protein composition of serum samples based on LC-MS data.

P2888

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1757-2215-3-21

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Rachel Isaksson Vogel

P577

2010-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46218312

http://www.w3.org/2001/XMLSchema#string

P6179

1014789191

http://www.w3.org/2001/XMLSchema#string

P698

20831812

http://www.w3.org/2001/XMLSchema#string

P921

P932

2949730

http://www.w3.org/2001/XMLSchema#string